Effects of Bone Marrow Stromal Cells and Umbilical Cord Blood-Derived Stromal Cells on Daunorubicin-Resistant Residual Jurkat Cells

Li, Xue; Liu, Hao; Chen, X.; Zhang, X.; Kong, Peiyan; Peng, Xiaoyong; Gao, Lei; Zhang, C.; Wang, Q.

doi:10.1016/j.transproceed.2010.08.055

Cited by 7 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast MSCs of adipose tissue (AT-MSCs) do not inhibit the proliferation of Jurkat cells 9. Our study showed that UC-MSCs suppressed proliferation and promoted apoptosis, differentiation, and drug sensitivity of Jurkat cells 10. We also observed that UC-MSCs can inhibit the growth and induce the apoptosis of tyrosine kinase inhibitor-resistant Philadelphia-positive ALL (unpublished data).…”

Section: Mscs In Anticancer Therapiessupporting

confidence: 65%

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

Zhang¹,

Yang²,

Qin³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression and metastasis, but also has profound effects on therapeutic efficacy. Stromal cells of the TME are increasingly becoming a key consideration in the development of active anticancer therapeutics. However, dispute concerning the role of stromal cells to fight cancer continues because the use of mesenchymal stem/stromal cells (MSCs) as an anticancer agent is dependent on the specific MSCs subtype, in vitro or in vivo conditions, factors secreted by MSCs, types of cancer cell lines and interactions between MSCs, cancer cells and host immune cells. In this review, we mainly focus on the role of human-derived normal MSCs in anticancer therapies. We first discuss the use of different MSCs in the therapies for various cancers. We then focus on their anticancer mechanism and clinical application.

show abstract

Section: Mscs In Anticancer Therapiessupporting

confidence: 65%

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

Zhang¹,

Yang²,

Qin³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

show abstract

“…It seems that among the MSCs which that originate from umbilical cord /cord blood (UC-MSCs) show more anti-cancer properties. Many studies report that UC-MSCs not only suppress tumor progression, but also promote drug sensitivity of different blood cancer cells including Jurkat leukemia cells [ 138 ], K562 erythromyeloblastoid leukemia cells [ 139 ], Burkitt's limphoma cells [ 140 ] and multiple myeloma cells [ 141 ]. In addition, UC-MSCs exert a suppressive effect on tumor growth of several solid tumor cell lines: breast cancer [ 142 ], liver cancer [ 143 ], prostate and bladder cancer [ 144 ].…”

Section: Anti-tumorigenic Activity Of Mesenchymal Stem Cellsmentioning

confidence: 99%

Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype

et al. 2017

View full text Add to dashboard Cite

Multipotent mesenchymal stem cells (MSCs) are recruited into tumor microenvironment in response to multiple signals produced by cancer cells. Molecules involved in their homing to tumors are the same inflammatory mediators produced by injured tissues: chemokines, cytokines and growth factors. When MSCs arrive into the tumor microenvironment these are “educated” to have pro-metastatic behaviour. Firstly, they promote cancer immunosuppression modulating both innate and adaptive immune systems. Moreover, tumor associated-MSCs trans-differentiating into cancer-associated fibroblasts can induce epithelial-mesenchymal-transition program in tumor cells. This process determinates a more aggressive phenotype of cancer cells by increasing their motility and invasiveness and favoring their dissemination to distant sites. In addition, MSCs are involved in the formation and modelling of pre-metastatic niches creating a supportive environment for colonization of circulating tumor cells.The development of novel therapeutic approaches targeting the different functions of MSCs in promoting tumor progression as well as the mechanisms underlying their activities could enhance the efficacy of conventional and immune anti-cancer therapies.Furthermore, many studies report the use of MSCs engineered to express different genes or as vehicle to specifically deliver novel drugs to tumors exploiting their strong tropism. Importantly, this approach can enhance local therapeutic efficacy and reduce the risk of systemic side effects.

show abstract

“…52 Microenvironment-mediated drug resistance is not restricted to conventional DNA-damaging chemotherapy agents, 53,54 rather it applies to a broad spectrum of compounds and microenvironment compositions. [55][56][57][58][59][60][61][62][63][64][65][66][67] The magnitude of drug resistance varies depending on the particular tumour cell, stroma and therapeutic agent being evaluated, and is not universal across all cancers for a given drug. 53 The way by which the microenvironment can modify drug response may be related to: (1) activation of survival signals from soluble factors or cell adhesion molecules, 53,68,69 (2) impaired drug delivery, 70 (3) corrupted immune surveillance 71 and (4) stimulated tumour regrowth.…”

Section: The Tumour Environment and Resistance To Therapymentioning

confidence: 99%

Linking the future of anticancer metal-complexes to the therapy of tumour metastases

Bergamo¹,

2015

View full text Add to dashboard Cite

Cancer chemotherapy is almost always applied to patients with one or more diagnosed metastases and is expected to impact these lesions, thus providing significant benefits to the patient. The outcome of metastasis is determined by the interplay between the specific subpopulation of metastatic cells and host homeostatic factors in specific microenvironments. In clinical practice, metal-based drugs are represented by platinum compounds, which are constituents of a wide variety of chemotherapeutic regimens, and are only rarely active against tumour metastases unless they are combined with drugs that target specific pathways characterizing the malignancy of the tested tumour. On experimental grounds, a number of complexes based on ruthenium and other metals have been frequently studied in vitro using models and experimental conditions mimicking one or more steps of the metastatic process, such as invasion and migration. The ruthenium-based drug, NAMI-A, is the only one to have been subject to clinical testing for the treatment of metastatic tumours. The capacity of NAMI-A to modulate the relationship established between metastatic cells and their microenvironment suggests that metal-based drugs shall be viewed as an opportunity for the treatment of tumour metastases.

show abstract

Effects of Bone Marrow Stromal Cells and Umbilical Cord Blood-Derived Stromal Cells on Daunorubicin-Resistant Residual Jurkat Cells

Cited by 7 publications

References 16 publications

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype

Linking the future of anticancer metal-complexes to the therapy of tumour metastases

Contact Info

Product

Resources

About